Two different N-terminal extensions have been identified within class II bacteriocin precursors. The first one is a two-glycine-type leader peptide associated with a dedicated ATP-binding cassette transporter. The second is a signal peptide which directs the bacteriocin precursor to the general secretion machinery. Mesentericin Y105 is a class II anti-Listeria bacteriocin produced by Leuconostoc mesentemides Y105 via a dedicated transport system (DTS). To investigate heterologous expression systems capable of producing mesentericin Y105 in various hosts, two different secretion vectors were constructed. One of them, containing the mesentericin Y105 structural gene fused to the segment encoding the divergicin A signal peptide, was introduced into Escherichia coli, Leuconostoc subsp. and Lactococcus subsp. In E. coli, mesentericin Y105 production was linked to a putative periplasmic toxicity. To take advantage of this secretion system, the mesentericin Y105 precursor was also produced in E. coli. It was demonstrated that this pre-bacteriocin exhibited some antagonistic activity against Listeria. To allow for a comparison between the two different transport systems, mesentericin Y105 production using the vector containing the mesentericin Y105 structural gene and i t s DTS transporter operon was examined. The production of mesentericin Y105 was monitored by a new fast purification method followed by M S analysis. It was shown that, in Leuconostoc, the production of mesentericin Y105 is enhanced via the DTS compared to the general secretion pathway.
INTRODUCTION
Bacteriocins are proteinaceous compounds produced by many lactic acid bacteria (LAB) that typically inhibit the growth of closely related species. They were classified into four classes by Klaenhammer (1993) . Class I1 bacteriocins produced by LAB constitute the largest group so far characterized. They consist of small heatstable peptides possessing an N-terminal extension of t Present address: Cornell University, Department of Food Science and 18-24 residues that contains a conserved Gly-Gly processing site (positions -2 and -1). It has been shown that most of these class I1 bacteriocins are exported (Stoddard et al., 1992; Marugg et al., 1992; Bukhtiyarova et al., 1994; Axelsson & Holck, 1995; van Belkum et al., 1997) by at least two membrane-bound proteins that form their dedicated transport system (DTS). One of the two proteins belongs to the family of the ATP-dependent transporters (Higgins, 1992) . It was demonstrated that the cleavage of the N-terminal extension of the bacteriocin occurred concomitantly to the export of the peptide through the cytoplasmic membrane (Hivarstein et al., 1995) . The other protein bears a still unknown function but is postulated to be an accessory protein. It 0002-2519 0 1998 SGM On: Thu, 03 Jan 2019 01:37:10 F. BIET a n d O T H E R S is anchored to the membrane by its hydrophobic Nterminus (Franke et al., 1996) . Worobo et al. (1995) and Leer et al. (1995) described two new bacteriocins from LAB, divergicin A and acidocin B, respectively, which are exported by the general secretion pathway (GSP). Indeed, divergicin A and acidocin B are encoded as precursors bearing a signal peptide.
Because of the potential use of bacteriocins as food preservatives and because most industrial strains d o not produce such antagonistic peptides, interest in the heterologous expression of class I1 bacteriocins is rapidly growing. However, most of these bacteriocins display a narrow spectrum of activity. Therefore, it may be possible to design strains that are capable of producing multiple bacteriocins targeting various species. Such an approach will require a large amount of genetic material. Indeed, the production of each bacteriocin requires the cloning of at least four genes, including the bacteriocin structural gene and its immunity gene in addition to the two genes encoding the DTS. Thus, the use of the GSP for the production of bacteriocins or the use of a single DTS for the transport of multiple bacteriocins are promising approaches. Worobo et al. (1995) and McCormick et al. (1996) showed that a protein or a peptide fused to the divergicin A signal peptide is efficiently exported and correctly matured by both Gram-positive and Gram-negative bacteria. In addition, the ability of the heterologous DTS to export class I1 bacteriocins has been demonstrated (Marugg et al., 1992; Fremaux et al., 1995; Allison et al., 1995a, b ; van Belkum et al., 1997 ). It appears that the level of bacteriocin production was greatly affected and was dependent on the level of homologies existing between the leader peptides of the bacteriocins.
Mesentericin Y 105 is a class I1 anti-listeria bacteriocin produced by Leuconostoc mesenteroides (Hichard et al., 1992) that may have application in food preservation. Its genetic determinants have been characterized and its export using the DTS has been suggested (Fremaux et af., 1995) . Lactacin F is another class I1 bacteriocin produced by Lactobacilfus johnsonii (Muriana & Klaenhammer, 1987) . The heterologous expression of inesentericin Y 105 was investigated in Lb.
johnsonii using the DTS of lactacin F; however, very poor expression of mesentericin Y 105 was obtained (Fremaux et al., 1995) . Thus, in this study, the efficiency of the GSP for expression of mesentericin Y105 was evaluated using the signal peptide of divergicin A. In addition, by cloning the mesentericin Y105 gene clusters including their putative DTS coding genes, the expression of mesentericin Y105 was tested in various Gram-positive hosts.
METHODS
Bacterial strains and plasmids. Bacterial strains and plasmids used in this study are listed in Table 1 . Escherichia cofi DH5a was propagated on Luria-Bertani agar (1*5%, w/v) or in broth at 37 "C with shaking as described by Sambrook et a f . (pH 6-8) . The samples were heated for 10 min at 100 "C and loaded on a 16% (v/v) polyacrylamide gel in 0.1 M Tris/Tricine (pH 8.8) buffer (Schagger & von Jagow, 1987) , which allowed suitable resolution of low-molecular-mass peptides. Electrophoresis was carried out at constant voltage (100 V) for 2 h. Gels were fixed in 50% (v/v) methanol and 10% (v/v) aqueous acetic acid for 20 min. Duplicate gels were performed. One of them was stained with Coomassie brilliant blue R250 to evaluate the molecular mass of the molecules contained in the sample. The second gel was washed with sterile water for 2 h, placed on a BHI agar plate and overlaid with 5 ml BHI agar (0.6 %, w/v) inoculated with 1 ' / o (v/v) of a stationary phase culture of List. ivanovii BUG 497. The inhibition zones were examined after 18 h incubation at 37 "C.
Molecular cloning and transformation.
Plasmids from E . cofi and LAB were extracted and purified as previously described by Sambrook et a f . (1989) and Muriana & Klaenhammer (1987) , respectively. Plasmid DNA was digested with restriction enzymes (Gibco-BRL) according to the supplier's recommendations. Both analytical and preparative agarose gel electrophoresis in Tris/borate/EDTA (pH 8.3) were performed according to the methods described by Sambrook et a f . (1989) . DNA restriction fragments were purified from agarose gels using the Prep-a-Gene kit (Bio-Rad) . Recombinant DNA was obtained using T 4 DNA ligase (Gibco-BRL) following the manufacturer's recommendations. E. cofi competent cells were prepared and transformed according to Hanahan (1983) . DNA sequences were determined with an automated DNA sequencer (ALF ; Pharmacia) using the Auto-read sequencing kit (Pharmacia) and appropriate primers. Sequence analyses were performed with the GCG sequence analysis software.
Oligonucleotides and PCRs. Primers FBpl (5'-AAGAAGCT-TCTGCTAAGTATTATGGGAATGGTG) and FBp2 (5'-CTCAAGCTTACTGATCGAAAACGCTG) were used for the PCR amplification of the fragment devoted to the secretion Fremaux et al. (1995) of mesentericin Y105 ( Fractions were assayed for bacteriocin activity by the spot-onlawn test. Reverse-phase HPLC was conducted on a Spectra Physics Analytical apparatus. Lyophilized active fractions were solubilized in 1 ml water before injection on a C8 column Kromasil (250 by 4.6 mm, 5 pm particle size, 10 nm pore size, flow rate 0.8 ml min-'). Separation was carried out using a water/acetonitrile/trifluoroacetic acid, 0. 37 min. Elutions were monitored by measuring the A,,, and A,,,. All fractions corresponding to the detected peaks were assayed for activity against the indicator strains.
Protein analysis. The mass spectra of the purified mesentericin Y 105 samples were obtained from positive ionspray analysis on a Perkin-Elmer Sciex API 165 mass spectrometer equipped with an ionspray source. Lyophilized active samples purified by HPLC were dissolved in a 0.25 ml solution of acetonitrile/ water (1 : 1) containing 0.1 O h formic acid and infusion injected (10 pl) at a flow rate of 5 p1 min-'. Protein concentration was determined by using the bicinchoninic acid protein assay kit (Sigma) according to the manufacturer's instructions.
RESULTS
Heterologous production of mesentericin Y 105 and its precursor using the GSP in E. coli
Preliminary experiments performed in E. coli strains attempted to investigate the secretion of mesentericin Y105 by the GSP. A secretion vector, pFBYCO1, was constructed on the basis of the utilization of the divergicin A signal peptide placed under the control of the inducible lac promoter, as described in Fig. 2 . T o generate pFBY CO1, the EcoRV-Hind111 fragment from pCD3.4 containing a ribosomebinding site and part of the divergicin A signal peptide gene was cloned into pBSSKII+ restricted with SmaI and Hind111 enzymes.
To obtain a DNA fragment encoding a mature form of mesentericin Y 105 and its immunity protein, a region of pHY3O (Fremaux et al., 1995) was amplified by PCR using the primers FBpl and FBp2 (Fig. la) . The Ala-SerAla cleavage site of the divergicin signal peptide, which is truncated in the EcoRV-Hind111 fragment, was regenerated by the residues incorporated into the sequence of the PCR primer FBpl. The PCR fragment was digested with HindIII and cloned into pFBYCOl at the unique Hind111 site to form the mesentericin Y105 secretion plasmid pFBY C02 (Fig. 2) . Sequence analysis confirmed the accuracy of the gene fusion and ensured that the correct reading frame was maintained between the sequence encoding the divergicin A signal peptide and the mesentericin Y105 structural gene, devoid of its natural leader peptide. In this construction, the transcription of the fused gene is under the control of the inducible lac promoter on pBSSKII + . Sequence analysis also revealed the presence of a small ORF, beginning from the lacZ start codon, which overlaps the fused gene and its translation initiation signals (the ribosomebinding site and the start codon of dvnA). To prevent any inefficient recognition of these signals, the Sac1 restriction site located within this small ORF was opened and then blunt-ended before ligation, generating a shift in the reading frame and stop codons. Secretion of mesentericin Y 105 was tested by introducing pFBY C02 into E . coli DH5a cells. Upon induction with 1 mM IPTG at an ODGoo of 1 (1 cm cuvette, Hitachi U-1100 spectrophotometer), the expression of an antagonistic activity within the culture supernatant was detected by the spot-on-lawn test against a sensitive indicator strain. The activity was then analysed by an SDS-PAGE overlay assay (Fig. 3) . The apparent molecular mass of the active peptide secreted by E. coli (Fig. 3, lane 1 ) was in accordance with that of the natural bacteriocin used as a control (Fig. 3, lane 4) . Full ind Liction of the antagonist in E. coli DHSa caused a declint. of the culture turbidity, suggesting the lysis of induced cells (data not shown).
The biochemical and structural characterization of the mesentericin Y 105 precursor will first require its purification. However, it is likely to be transirorily present in the natural mesentericin Y 105 producer strain and therefore difficult to purify. Consequently, we constructed the plasmid pFBYC03 to secrete the mesentericin Y105 precursor (Fig. 2) . For pFBYC03 construction, the cloning strategy was identical to that described for pFBYC02, except that the PCR fragment (using primers FBp2 and FBp3) cloned into the HindIII site of pFBYCOl contains the whole structural gene of mesentericin Y105, including the part encoding the Nterminal extension of mesentericin Y 105 (Fig. 1 b) . After transformation of pFBYC03 into E. coli DH5a and induction of the cloned gene, the presence of an active peptide against Listeria was determined by an SDS-PAGE overlay assay (Fig. 3) . This peptide has an apparent molecular mass higher than that of the natural mesentericin Y105, and thus is likely to be the premesentericin Y 105. From the SDS-PAGE overlay assay, it appeared to be less active compared to mesentericin Y105, as confirmed by the absence of cell lysis upon induction by IPTG (not shown).
Heterologous production of mesentericin Y 105 using the GSP in Leuconostoc
A secretion vector that replicates in LAB was developed using plasmid pRW5.6 constructed by Worobo et al. (1995) . In this plasmid, the divergicin A operon is under the control of the constitutive lactococcal promoter p59 (Fig. 2) . Plasmid pRW5.6 was digested with HindIII, deleting part of the divergicin A structural gene and its immunity gene, then self-ligated to construct pFBY C06 (Fig. 2) . Similarly to pFBYC02, a PCR-generated DNA (using primers FBpl and FBp2) encoding a mature form of mesentericin Y105 and its immunity protein with
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Heterologous production of mesentericin Y 105 using the DTS in Leuconostoc
Plasmid pCFYC5 contains the mesentericin Y105 structural gene (mesY) and its immunity gene (rnesl) (Fremaux et al., 1995) . When introduced into Ln. mesenteroides DSM 20484, the resulting strain failed to produce any bactericidal activity against Listeria or LAB, suggesting that some essential functions are missing within the cloned fragment for the production of the bacteriocin. Previous analyses of the mesentericin Y105 genetic locus (Fremaux et al., 1995) 
Analysis of mesentericin Y 105 expressed in Ln. mesen teroides
The antagonistic compound, produced by Ln. mesenteroides DSM ,20484 transformed with pFBY C04 and pFBY C07, was purified from cell-free culture supernatants by a three-step protocol involving ammonium sulfate precipitation, C18 solid-phase extraction and reverse-phase HPLC. Almost all of the antagonistic activity was found in the ammonium sulfate pellet. After resuspending this pellet in water, proteins were fractionated on C18 cartridges using an increasing acetonitrile step gradient. The active fraction eluted at 40% acetonitrile was further purified by reverse-phase HPLC. The elution profiles showed a single protein peak at a retention time of 22 min (peak A ; Fig. 4) . The biological activity of the HPLC fractions corresponding to the peaks was assayed against the indicator strain, revealing an antagonistic activity. The purified protein was subjected to MS analysis using an ionspray ionization source instrument. As shown in Fig. 5(a) , the final estimated mass was 3868.27 0.25 Da for the purified peptide from Ln. mesenteroides DSM 20484 containing either pFBYC04 or pFBYC07. This value corresponds to the molecular mass of mesentericin Y 105 purified from the supernatant of the natural producer strain Ln. mesenteroides Y105 (lane 1, peak A; Fig. 4) , and is in agreement with the theoretical molecular mass for an oxidized form of mesentericin Y105 calculated from its amino acid sequence (Fremaux et al., 1995) DSM 20484(pFBYC04) and Ln. mesenteroides Y 105 (142 and 129 pg, respectively), whereas 34 pg mesentericin Y 105 was obtained from Ln. mesenteroides DSM 20484( pFBY C07), under identical culture conditions and using the same purification procedure. In addition to peak A corresponding to mesentericin Y105, a second protein peak (lane 1, peak B; Fig. 4 ) was revealed on a HPLC chromatogram from a culture of the natural mesentericin Y105 producer. Peak B, with a 27.7 min retention time, showed an antagonistic activity against Leuconostoc strains (data not shown) but not Listeria, suggesting the production of a second bacteriocin. Indeed, it is not likely to correspond to a degradation product from mesentericin Y105, since it was not detected in Ln. mesenteroides DSM 20484(pFBYC04) culture supernatant. Mass spectrum analysis of peak B gave a molecular mass of 3445.95 & 0.35 Da (Fig. 5b) .
With respect to the molecular mass, this compound resembles mesenterocin 52B, previously described by Revol-Junelles et al. (1996) , a class I1 bacteriocin known for its activity against Leuconostoc strains but not Listeria. Our results demonstrate the production of a second bacteriocin by Ln. mesenteroides Y 105 that was not previously detected because mesentericin Y 105 masked its activity in spot-on-lawn tests.
Heterologous expression of mesentericin Y105 in Lc. lactis
T o further study the heterologous expression of mesentericin Y 105, plasmids pFBY C04 and pFBY C07 were also introduced into Lc. lactis strains IL1403 and RD230. The ability of the transformants to produce mesentericin Y105 was examined. None of the supernatants of Lc. lactislpFBYC04 or Lc. lactislpFBYCO7 transformants revealed any detectable antagonistic activity. These data cannot be correlated to a transcriptional deficiency, since Northern blot hybridization revealed the presence of the expected transcript (data not shown). To test if, in Lactococcus, mesentericin Y105 is expressed in an inactive form or alternatively is not present at all in the extracellular medium, we looked for its presence in the supernatant as described before. The HPLC chromatogram did not show any peak at a retention time of 22 min. This seems to confirm the inability to produce mesentericin Y105 from pFBYC07 or pFBYC04 in Lactococcus.
DISCUSSION
Large quantities of a bacteriocin are required for structural analysis. In attempts to obtain a sufficient amount of mesentericin Y 105 for elucidating its spatial conformation, we investigated its heterologous expression in various bacterial species using two export systems: (i) the GSP and (ii) the putative mesentericin Y105 DTS.
First, we took advantage of the divergicin A signal peptide for the construction of two plasmids (pFBYC03 and pFBYC02) capable of secreting the mesentericin Y105 precursor and the mature mesentericin Y 105, respectively. In these plasmids, the structural gene of mesentericin Y105 or the part of the gene encoding the mature peptide is fused to the signal peptide of the divergicin A encoding region. This synthetic gene was placed under the control of the /I-galactosidase inducible promoter. Cloned in E. cofi DHSa, the two plasmids allowed the production of both peptides. Interestingly, the bacteriocin precursor (that possessed a 24 N-terminal amino acid extension) exhibited a weak antagonistic activity against Listeria. This is in agreement with the observation by Quadri et al. (1997) for the carnobacteriocin B2 precursor. Previous work demonstrated the ability of E. coli to produce heterologous bacteriocins originated from LAB. Pediocin PA-1 was produced via its own DTS (Marugg et al., 1992) and divergicin A was exported using the leucocin A or colicin V export machinery (van Belkum et al., 1997) . On the contrary, divergicin A failed to be produced by E. coli using the lactococcin A DTS (van Belkum et al., 1997) . In our case, very poor antagonistic activity (about 100 times less than the natural producer) was detected in the supernatant of E. cofi DHSa(pFBYC02) cultures. Nevertheless, the divergicin A signal peptide was shown to efficiently direct the production of alkaline phosphatase to the culture supernatant in E . coli . However, these authors reported that one-third of the secreted alkaline phosphatase was located within the periplasm. In addition, although colicin V is efficiently secreted across the cytoplasmic membrane via the GSP, secretion through the outer membrane is not achieved and the molecule is trapped within the periplasm (Zhang et al., 1995) . Despite previous analyses demonstrating that mesentericin Y 105 was inactive on whole cells of E. coli, upon IPTG induction, cell lysis was observed in E. coli DHSa(pFBYC02) cultures. This result, together with the low level of production, suggested that at least a part of mesentericin Y 105 is trapped within the periplasm and that the toxicity of mesentericin Y105 may lead to cell lysis. Interestingly, a lytic activity of mesentericin Y 105 on mitochondria (Maftah et al., 1993) and erythrocytes (A. Maftah, personal communication) was previously described. These three lots of data suggest that mesentericin Y105 rnay act without the intermediate of a specific receptor when the cytoplasmic membrane is directly accessible. Thus, the cell wall is likely to give its specificity to the bacteriocin. The immunity protein may ensure the cytoplasmic membrane integrity and may not be expressed enough in the E. coli DHSa(pFBYC02) strain. Indeed, we were unable to construct an E. coli strain expressing mesentericin Y105 in which the immunity gene was disrupted, suggesting that pFBYC02 encodes a functional immunity protein in E. coli.
The toxicity of mesentericin Y 105 produced by a Gramnegative host led us to investigate the secretion of the bacteriocin in Lactococcus and Leuconostoc. Heterologous expression in Lc. lactis of bacteriocins fused to the divergicin A signal peptide has been investigated previously. Divergicin A and carnobacteriocin B2 were found to be secreted by Lc. lactis McCormick et al., 1996) , proving the efficiency of the GSP for the expression of bacteriocins in Gram-positive species. A plasmid (pFBYC07), based on the cloning vector pGKV259, was constructed in which the gene encoding the secreted mesentericin Y105 is under the control of the constitutive lactococcal promoter p59. Three lactococcal strains (laboratory strains IL1403 and MG1363 and one industrial strain RD230) transformed with pFBYC07 failed to produce any detectable amount of bacteriocin. Plasmid pFBYC07 was then isolated from one of the lactococcal transformants and used to transform Leuconostoc strains. In contrast to Lc. lactis strains, all the Leuconostoc transformants were found to produce small amounts of mesentericin Y105 in the culture supernatant. Low level secretion of mesentericin Y 105 is consistent with the weak activity detected for the secreted divergicin A and carnobacteriocin B2 in heterologous hosts McCormick et al., 1996) .
Leucocin A is an anti-listeria peptide closely related to mesentericin Y105 (Hastings et al., 1991) . These two peptides only differ by two residues, alanine 22 (niesentericin Y 105) versus phenylalanine (leucocin A) and isoleucine 26 versus valine. These differences are conservative changes, and thus one can expect leucocin A to behave similarly to mesentericin Y105. Leucocin A has been produced previously in Lc. lactis, using its own DTS (van Belkum et al., 1997 Northern blot analysis proved that the mesentericin Y105 gene cluster in pFBYC04 and the dunA::mesY gene fusion in pFBYC07 were well transcribed in Lactococcus (data not shown). In addition, bacteriocin genes originating from LAB are usually efficiently translated in Lactococcus and this species was shown to be capable of exporting and processing a few bacteriocins from other LAB species van Belkum et al., 1997; Horn et al., 1998) . Thus, we suspect that difficulties encountered in producing mesentericin Y105, but not leucocin A, in Lactococcus may be associated with either peptide degradation or trapping specified by the bacteriocin sequence itself. Indeed, lactococcal strains are known to produce many peptidases (Kunji et al., 1996) and the binding properties of bacteriocins have been previously reported (Coventry et al., 1996) . It is, however, interesting to note that failure to produce a bacteriocin using its own DTS in a heterologous host has already been described (van Belkum et al., 1997) .
The level of mesentericin Y105 expression by recombinant and wild-type Leuconostoc strains was evaluated through a new three-step purification method.
This mesentericin Y 105 purification strategy appeared to be highly reproducible and more efficient than previously described methods (HCchard et al., 1992; Revol-Junelles et al., 1996) . Comparison of the yield of purified bacteriocin showed that mesentericin Y 105 is produced about three times more when exported by its own DTS, i.e. > 1 mg I-' for cultures of Ln. mesenteroides Y105 and Ln. mesenteroides DSM 20484-(pFBYC04) , than by the GSP, i.e. -300 pg1-l for a culture of Ln. mesenteroides DSM 20484(pFBYC07).
However, this may be not only related to the efficiency of the export system itself (DTS versus GSP), but also to gene copy numbers (pTRKH2 versus pGKV2.59) and/or promoter efficiencies (mesentericin Y 105 promoter versus p59 promoter).
Very few industrial LAB are known to produce bacteriocins. To take advantage of these GRAS (Generally Recognized As Safe) antagonistic peptides in the control Heterologous expression of mesentericin Y 105 of spoilage and pathogenic bacteria, various strategies have been proposed previously to produce bacteriocins in heterologous hosts, especially in industrial strains. The secretion pathway appeared to be a 'premium' choice because of its ubiquity among bacteria. The feasibility of bacteriocin secretion has been shown McCormick et al., 1996) . However, we demonstrated that bacteriocin yield was poor and may not fit industrial requirements. Some authors also investigated the possibility of producing multiple bacteriocins using the DTS of other bacteriocins (Allison et al., 1995a, b ; Fremaux et al., 1995; . They demonstrated the poor efficiency of such heterologous association, suggesting that DTSs are someway specific for a bacteriocin. Thus, the leader peptide associated with its own DTS fused to a mature peptide seemed to be an attractive alternative. However, at least for mesentericin Y10.5, the primary sequence of the bacteriocin affects the efficiency of its expression. Therefore, it appears that the best compromise consists in the production of bacteriocins by strains of 'homologous genera' using their own DTS. For example, we were able to express the mesentericin Y105 in an industrial strain, namely Ln. cremoris LC, at a similar level to that of the natural producer. In addition, such approaches are more likely to be in accordance with legal issues concerning the release of genetically modified micro-organisms.
